ImpediMed
Sydney, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Australian med‑tech firm delivering FDA‑cleared BIS diagnostics for fluid‑status monitoring across oncology, cardiology and metabolic care.
OncologyCardiologyMetabolismWellness
Technology Platform
Bioimpedance Spectroscopy (BIS) measuring 256 frequencies in a rapid scan to separate intra‑ and extracellular fluid, integrated into the cloud‑connected SOZO digital health platform for real‑time clinical decision support.
Opportunities
Expansion into heart‑failure and obesity management programs, integration with tele‑health platforms, and broader international reimbursement pathways.
Risk Factors
Dependence on payer reimbursement, adoption barriers in entrenched clinical workflows, and competition from alternative fluid‑monitoring technologies.
Competitive Landscape
Competes with other BIS vendors (e.g., ImpediV, LymphAssist) and emerging wearable fluid‑sensing devices; differentiation lies in FDA clearance, multi‑frequency analysis, and a fully integrated cloud platform.